The pharmaceutical product Marinol, a synthetic form of THC known as dronabinol, is identified as a competitor to natural marijuana. Solvay Pharmaceuticals, the maker of Marinol, was recently acquired by Abbott Labs. The segment suggests that the government's continued crackdown on natural marijuana is intended to protect the market share of patented synthetic alternatives.
